Article Information
History
- November 22, 2020.
Article Versions
- Version 1 (October 11, 2020 - 05:30).
- Version 2 (October 16, 2020 - 11:24).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Emily Peach, Research Fellow1,
- Megan Rutter, Clinical Research Fellow1,
- Peter Lanyon, Consultant Rheumatologist and Honorary Clinical Associate Professor3,
- Matthew J Grainge, Associate Professor in Medical Statistics1,
- Richard Hubbard, Professor of Epidemiology and Honorary Respiratory Consultant1,
- Jeanette Aston, NCARDRS rare disease data liaison6,
- Mary Bythell, NCARDRS Head of Rare Disease6,
- Sarah Stevens, Interim Deputy Director6 and
- Fiona Pearce, Clinical Associate Professor of Rheumatology Epidemiology1,*
- 1Division of Epidemiology and Public Health, University of Nottingham UK
- 3Nottingham University Hospitals NHS Trust, Nottingham, UK
- 6National Disease Registration Service, Public Health England
- ↵*Correspondence to: Fiona Pearce, Clinical Sciences Building, City Hospital campus, Hucknall Road, Nottingham, NG5 1PB, Fiona.Pearce{at}nottingham.ac.uk
Posted November 22, 2020.
Risk of death among people with rare autoimmune diseases compared to the general population in England during the 2020 COVID-19 pandemic
